<?xml version="1.0" encoding="UTF-8"?>
<ref id="BST-47-1757C76">
 <label>76</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Graves</surname>
    <given-names>P.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Aponte-Collazo</surname>
    <given-names>L.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Fennell</surname>
    <given-names>E.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Graves</surname>
    <given-names>A.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Hale</surname>
    <given-names>A.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Dicheva</surname>
    <given-names>N.</given-names>
   </name>
   <etal>et al.</etal>
  </person-group> (
  <year>2019</year>) 
  <article-title>Mitochondrial protease ClpP is a target for the anticancer compounds ONC201 and related analogues</article-title>. 
  <source>ACS Chem. Biol.</source>
  <volume>14</volume>, 
  <fpage>1020</fpage>â€“
  <lpage>1029</lpage>
  <pub-id pub-id-type="doi">10.1021/acschembio.9b00222</pub-id>
  <pub-id pub-id-type="pmid">31021596</pub-id>
 </mixed-citation>
</ref>
